Trials / Completed
CompletedNCT04474197
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-864 in PiZZ Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-864 in PiZZ subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-864 | Tablets for oral administration. |
| DRUG | Placebo | Placebo matched to VX-864 for oral administration. |
Timeline
- Start date
- 2020-07-24
- Primary completion
- 2021-05-04
- Completion
- 2021-05-04
- First posted
- 2020-07-16
- Last updated
- 2022-05-26
- Results posted
- 2022-05-26
Locations
30 sites across 6 countries: United States, Canada, Germany, Ireland, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04474197. Inclusion in this directory is not an endorsement.